AKRO News and Press, Akero Therapeutics Inc. From 09/09/20

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders...

Introduction It’s closing in on almost 3-years since I first published my initial write-up on Viking Therapeutics ( VKTX ) back in Oct-2017. I’ve had plenty to say about the company since that time, publishing numerous other articles along the way, but more recently I’...

Akero Therapeutics (NASDAQ: AKRO ) : Q2 GAAP EPS of -$0.57 beats by $0.05 . More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SAN FRANCISCO , Aug. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, toda...

Biotech Pulse Biotechs continue to be one of the leading healthcare groups and along with diagnostics represent two of the best segments of healthcare. The first half saw biotechs recover quicker from the March selloff than most of the market, and reach a milestone that took 5 years to achie...

SOUTH SAN FRANCISCO, Calif. , July 21, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic, non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance, today announced the publication of data in the ...

Akero Therapeutics (NASDAQ: AKRO ) closes upsized public offering at gross proceeds of ~$216.4M for 6M shares with the underwriters' option to purchase additional shares exercised in full. More news on: Akero Therapeutics, Inc., Healthcare stocks news, , Read more ...

SOUTH SAN FRANCISCO, Calif. , July 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients,&...

Akero Therapeutics (NASDAQ: AKRO ) has priced its public offering of 5,228,166 common shares at $36.00/share, for expected gross proceeds of ~$188.2M. More news on: Akero Therapeutics, Inc., Healthcare stocks news, , Read more ...

SOUTH SAN FRANCISCO, Calif. , July 7, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients,&#...